Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Front Immunol. 2022 Jul 28;13:915578. doi: 10.3389/fimmu.2022.915578. eCollection 2022.
Pharmacotherapeutic management of immune-mediated inflammatory diseases (IMID) has become more complex due to the development of new treatments, such as biological therapies. Mobile health, especially apps, can provide IMID patients with greater autonomy and facilitate communication with healthcare professionals. Our objective was to design and implement an app for remote monitoring and communication with IMID patients.
A multidisciplinary group was created to design and develop an app for IMID patients in a tertiary hospital. The app functionalities were identified through a focus group with IMID patients and through an observational, descriptive study of available apps for IMID patients at App Store and Play Store platforms. Once the app was designed and developed, we offered the app to IMID patients who initiated a new biological therapy. The inclusion period was from December 2020 to August 2021. We performed an observational, longitudinal study to assess the app's impact on medication safety, communication, satisfaction, and usability.
We designed an app (eMidCare) with the following modules: My Medication, My Questionnaires, Adverse Events, Useful Information, Messages, and Patient Profile. A total of 85 patients were installed with the app. The median (range) follow-up time for app use was 123 (5-270) days. In the My Medication module, 100% of patients registered their biological therapy and 25.9% also used this module to record each dose of medication administered. A total of 82 adverse events (AEs) were registered. Thirty-two percent of the patients registered at least 1 AE. The most frequent AEs were fatigue, injection site reaction, headache, and nausea. Fifty-two percent of patients used the Messages module to communicate with healthcare professionals. The most frequent messages concerned doubts about managing AEs (26.2%) and drug interactions (18.9%). The satisfaction survey yielded a median (range) score of 9.1 (7-10) out of 10.
We developed an app, eMidCare, which reminds patients to take their medication, enables them to record AEs, and helps them communicate with healthcare professionals. Approximately one-third of the patients registered the administration of the biological therapies and registered at least 1 AE. The most used and most satisfactory functionality was communication with health professionals.
由于新型治疗方法（如生物疗法）的发展，免疫介导的炎症性疾病（IMID）的药物治疗管理变得更加复杂。移动医疗，尤其是应用程序，可以为 IMID 患者提供更大的自主权，并促进与医疗保健专业人员的沟通。我们的目标是设计和实施一种用于远程监测和与 IMID 患者沟通的应用程序。
创建了一个多学科小组，以在一家三级医院为 IMID 患者设计和开发一款应用程序。通过与 IMID 患者进行焦点小组讨论，并对 App Store 和 Play Store 平台上现有的 IMID 患者应用程序进行观察性、描述性研究，确定了应用程序的功能。设计和开发完应用程序后，我们向开始使用新的生物疗法的 IMID 患者提供该应用程序。纳入期为 2020 年 12 月至 2021 年 8 月。我们进行了一项观察性、纵向研究，以评估该应用程序对药物安全性、沟通、满意度和可用性的影响。
我们设计了一个名为 eMidCare 的应用程序，其中包含以下模块：我的药物、我的问卷、不良事件、有用信息、消息和患者资料。共有 85 名患者安装了该应用程序。应用程序使用的中位（范围）随访时间为 123（5-270）天。在“我的药物”模块中，100%的患者登记了他们的生物治疗药物，25.9%的患者还使用该模块记录每次给药的剂量。共登记了 82 例不良事件（AE）。32%的患者登记了至少 1 例 AE。最常见的 AE 是疲劳、注射部位反应、头痛和恶心。52%的患者使用“消息”模块与医疗保健专业人员进行沟通。最常见的消息是关于管理 AE（26.2%）和药物相互作用（18.9%）的疑问。满意度调查得出的中位数（范围）评分为 10 分制中的 9.1（7-10）分。
我们开发了一款名为 eMidCare 的应用程序，该应用程序可以提醒患者服药、记录 AE，并帮助他们与医疗保健专业人员沟通。大约三分之一的患者登记了生物治疗药物的使用情况，并登记了至少 1 例 AE。使用最多和最满意的功能是与健康专业人员沟通。
